<DOC>
	<DOCNO>NCT00082966</DOCNO>
	<brief_summary>Phase II trial study effectiveness bortezomib treat patient relapsed refractory Hodgkin 's lymphoma . Bortezomib may stop growth cancer cell block enzymes necessary growth .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy bortezomib patient relapsed refractory Hodgkin 's lymphoma use overall response rate primary efficacy endpoint . II . To assess time progression 2-year overall survival bortezomib therapy . III . To evaluate safety tolerability bortezomib patient relapsed/refractory Hodgkin 's lymphoma . OUTLINE : This multicenter study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 8 course absence rapid disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm classical Hodgkin 's lymphoma No bone marrow biopsy fine needle aspirate sole mean diagnosis Core biopsy allow contain adequate tissue primary diagnosis The following subtypes allow : Nodular sclerosis Lymphocyte rich Mixed cellularity Lymphocyte depletion Classical Hodgkin 's lymphoma , otherwise specify No nodular lymphocytepredominant Hodgkin 's lymphoma Relapsed refractory disease least 1 prior standard systemic cytotoxic chemotherapy regimen Measurable disease physical exam image study Any tumor mass &gt; 1 cm allow No nonmeasurable disease , include follow : Bone lesion Ascites Pleural pericardial effusion Lymphangitis cutis/pulmonis Bone marrow No curative option available highdose therapy stem cell transplantation Performance status 02 Absolute neutrophil count ≥ 750/mm^3 Platelet count ≥ 75,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN Creatinine ≤ 2.5 mg/dL No sensory motor peripheral neuropathy ≥ grade 2 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation See Disease Characteristics Prior stem cell transplantation allow See Disease Characteristics No concurrent chemotherapy No concurrent dexamethasone steroidal antiemetic Concurrent steroid adrenal failure allow Concurrent hormonal therapy nondisease relate condition ( e.g. , insulin diabetes ) allow Prior radiotherapy symptomatic lesion one may produce disability ( e.g. , unstable femur ) allow provide measurable disease present No concurrent palliative radiotherapy Recovered prior treatment No prior bortezomib proteosome inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>